Which therapy for which patient?

  title={Which therapy for which patient?},
  author={Giulia Pierangeli and Sabina Cevoli and Elisa Sancisi and Daniela Grimaldi and Stefano Zanigni and Pasquale Montagna and Pietro Cortelli},
  journal={Neurological Sciences},
Prophylactic treatment is mainly intended to reduce the frequency of migraine attacks, enhance response to acute medications, improve patient function and reduce disability. Sufficient evidence and consensus exist to recommend propranolol, timolol, amitriptyline, pizotifen, divalproex, sodium valproate and topiramate as first line agents for migraine prevention. These drugs can halve the frequency of attacks in 50% of patients. The anticipated benefit must be weighed against the adverse effects… 

Pizotifen in migraine prevention: A comparison with sodium valproate

Background & Objective: Pizotifen is an alternative option for prophylactic treatment of migraine headache. This study aims to compare the effi cacy and safety of pizotifen with sodium valproate; one

Interaction of Valproic Acid and Amitriptyline: Analysis of Therapeutic Drug Monitoring Data Under Naturalistic Conditions

A cautious dosing of AMi with VPA comedication is advisable, and therapeutic drug monitoring should be performed because this combination may lead to a remarkable increase of AMI and NOR serum levels.

Improving care through health economics analyses: cost of illness and headache

The notion of cost of illness is explained, examining how it could be applied in such a framework and the relationship between costs and quality of life for people affected by headache disorders is shifted on.

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

The pathophysiological mechanisms of the psoriasis and cardiometabolic interplay are presented, the view on the interaction of ps oriasis and cardiovascular disease is reviewed, and the atherosclerotic effect of therapeutic options used in psOriasis are reviewed, i.e., what the effect of medications used in the prevention of atherosclerosis could be on Psoriasis.

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Ustekinumab demonstrated a favorable and consistent safety profile across registrational trials in approved indications, and was significantly increased in patients who did versus those who did not receive corticosteroids.

Beta-adrenergic blockade and voice: a double-blind, placebo-controlled trial.

Emicrania: cenni di fisiopatologia e la terapia

L’emicrania e una condizione patologica complessa che potrebbe essere considerata una tendenza ereditaria ad avere cefalea, accompagnata a sintomi vegetativi e ad ipersensibilita a diversi stimoli.

A Validated RP-HPLC Method for the Estimation of Pizotifen in Pharmaceutical Dosage Form

A simple, selective, linear, precise, and accurate RP-HPLC method was developed and validated for rapid assay of Pizotifen in pharmaceutical dosage form. Isocratic elution at a flow rate of 1.0

Analytical Method Development and Validation of Pharmaceutical Analysis Using Chromatographic Techniques

The purpose of this special issue will be to serve as a guide to what chromatographic methods bring to analytical and medicinal chemistry and other pharmaceutical sciences as well as briefly review their role in drugs and the new developments and validation of assay methods of pharmaceutically active compounds.



Preventive treatment of migraine.

  • S. Silberstein
  • Medicine, Psychology
    Reviews in neurological diseases
  • 2005

How do the Currently Used Prophylactic Agents Work in Migraine?

  • P. Goadsby
  • Biology
    Cephalalgia : an international journal of headache
  • 1997
The actions and indeed the locus of action of the preventatives is crucial since these drugs are likely to point to the basic defect which underlies the process responsible for a migraine attack.

General Principles of Migraine Management: The Changing Role of Prevention

The possibility that timely use of prophylactic treatment might modify or prevent the transformation to chronic migraine and the extreme disability that characterizes a small but significant subset of the migraine population is raised.

Anticonvulsant drugs for migraine prophylaxis.

It is demonstrated that anticonvulsants, considered as a class, reduce migraine frequency by about 1.4 attacks per 28 days as compared to placebo, and two recently published and large trials of topiramate demonstrated reasonable efficacy, and one further trial of this agent is anticipated in the near future.

Bending the Rule of Monotherapy for Migraine Prevention?

A 32-year-old woman has migraine without aura and was on monotherapy with therapeutic doses of amitriptyline, topiramate, and extended release divalproex sodium without benefit, but would benefit from the addition of a second preventive medication.

Combined Therapy for Migraine Prevention? Clinical Experience with A β-Blocker Plus Sodium Valproate in 52 Resistant Migraine Patients

From this open trial, combination therapy with a β-blocker and sodium valproate appears to be a good migraine preventative in some previously resistant migraine cases.

Migraine treatment throughout the lifecycle

  • S. LandyB. Lobo
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2005
The pathophysiology of migraine is reviewed, with a special emphasis on the evolving concept of central sensitization and cutaneous allodynia since this concept has led to a paradigm shift in the way migraines are managed.

Comparison of the Effects of Amitriptyline and Flunarizine on Weight Gain and Serum Leptin, C Peptide and Insulin Levels when used as Migraine Preventive Treatment

A result from this study indicates that AMT and flunarizine may cause leptin resistance possibly by different mechanisms and thereby result in increase in serum leptin levels and BMI.

Behavioral treatment of migraine: current status and future directions

  • F. Andrasik
  • Psychology
    Expert review of neurotherapeutics
  • 2004
The empirical support for three behavioral treatments (relaxation, biofeedback and cognitive therapy) for managing migraine headaches in children and adults is reviewed. Meta-analyses and

Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache

This guideline applies to patients with acute migraine attacks, with or without aura, and patients with migraine who are candidates for preventive drug therapy, and the target audience for this guideline is primary care physicians.